Cite
HARVARD Citation
Dörner, T. et al. (n.d.). OP0302 IANALUMAB (VAY736), A DUAL MODE OF ACTION BIOLOGIC COMBINING BAFF RECEPTOR INHIBITION WITH B CELL DEPLETION, REACHES PRIMARY ENDPOINT FOR TREATMENT OF PRIMARY SJOGREN'S SYNDROME. Annals of the rheumatic diseases. pp. 187-188. [Online].